Cargando...
Harnessing the Immune System in Pancreatic Cancer
Managing patients with metastatic pancreatic adenocarcinoma (mPDA) is a challenging proposition for any treating oncologist. Although the potency of first-line therapies has improved with the approvals of FOLFIRINOX and gemcitabine plus nab-paclitaxel, many patients are unable to derive significant...
Gardado en:
| Publicado en: | Curr Treat Options Oncol |
|---|---|
| Main Authors: | , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
2018
|
| Assuntos: | |
| Acceso en liña: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6524529/ https://ncbi.nlm.nih.gov/pubmed/30128712 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s11864-018-0566-5 |
| Tags: |
Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|